Article

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer

2024-07-12

Abstract excerpt

In advanced castration resistant prostate cancer (CRPC), mutations in the DNA damage response (DDR) gene ataxia telangiectasia mutated ( ATM ) are common. While poly(ADP-ribose) polymerase inhibitors are approved in this context, their clinical efficacy remains limited. Thus, there is a compelling need to identify alternative therapeutic avenues for ATM mutant prostate cancer patients. Here, we generated matche...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4da336e6-5f72-5770-8107-c4677ce22652
DOI: 10.1101/2024.07.10.602941

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancerDOI 10.1101/2024.07.10.602941Read

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read

ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerSemantic proximity Read

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancerSemantic proximity Read

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsSemantic proximity Read

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read

Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerSemantic proximity Read

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read